Menu Search
Equities

Agenus Inc

AGEN:NAQ

Agenus Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.84
  • Today's Change-0.150 / -2.50%
  • Shares traded978.97k
  • 1 Year change-75.67%
  • Beta1.3566
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Agenus Inc had net income fall 11.67% from a loss of 220.07m to a larger loss of 245.76m despite a 59.47% increase in revenues from 98.02m to 156.31m.
Gross margin99.51%
Net profit margin-144.94%
Operating margin-71.18%
Return on assets-68.45%
Return on equity--
Return on investment-281.52%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Agenus Inc fell by 101.56m. Cash Flow from Financing totalled 119.87m or 76.68% of revenues. In addition the company used 224.20m for operations while cash from investing totalled 3.40m.
Cash flow per share-10.90
Price/Cash flow per share--
Book value per share-11.42
Tangible book value per share-12.79
More ▼

Balance sheet in USDView more

Agenus Inc uses little or no debt in its capital structure.
Current ratio0.3695
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.